Dallas, TX, United States of America

Zhu Chen

This inventor holds 4 USPTO granted patents. Top assignee: The University of Texas System. Active years: 2000-2006.


% Patents Active = 75.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Location History:

  • New York, NY (US) (2003)
  • Dallas, TX (US) (2000 - 2006)

Company Filing History:


Years Active: 2000-2006

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Zhu Chen in Protein Kinase Research

Introduction

Zhu Chen is a prominent inventor based in Dallas, TX (US). He has made significant contributions to the field of protein kinase research, holding a total of 4 patents. His work focuses on the development of compositions and methods that enhance the activity of specific mitogen-activated protein kinases.

Latest Patents

Zhu Chen's latest patents include innovative approaches to potentiating the activity of the mitogen-activated protein kinase p38. His research specifically addresses the mitogen-activated protein kinase kinase MEK6 and its variants, which stimulate the phosphorylation of p38. These compounds have potential therapeutic applications for diseases associated with the p38 cascade. Additionally, they can be utilized to identify antibodies and other agents that either inhibit or activate signal transduction via p38.

Career Highlights

Zhu Chen is affiliated with the University of Texas System, where he continues to advance his research in protein kinases. His work has garnered attention for its potential impact on therapeutic strategies for various diseases.

Collaborations

Zhu Chen collaborates with notable colleagues, including Kevin Berman and Melanie H Cobb, who contribute to his research endeavors.

Conclusion

Zhu Chen's innovative work in the field of protein kinases exemplifies the importance of research in developing therapeutic solutions. His contributions are paving the way for advancements in medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…